EyePoint Pharmaceuticals, Inc.
Hedge Funds Holdings
Last updated:
EyePoint Pharmaceuticals, Inc.‘s stocks are currently a part of 34 hedge funds’ portfolios, which represents 25.31% of the total amount of its stocks outstanding. This makes up a total of 9.44M shares of EyePoint Pharmaceuticals, Inc.. Compared to the previous quarter, the number fell by -67.85% or -19.92M shares fewer. As for the holding position changes, 26.47% (9) of current hedge fund investors increased the number of shares held, 29.41% (10) of current holders sold a part of the shares held, and 26.47% (9) closed the holdings completely. 5 hedge funds are new holders of EyePoint Pharmaceuticals, Inc. stock in Q1 2023, it is 14.71% of total holders.
Hedge funds holding EyePoint Pharmaceuticals (Q2 2018 – Q1 2023)
| Q2 2018 | 34 |
|---|---|
| Q3 2018 | 34 |
| Q4 2018 | 44 |
| Q1 2019 | 56 |
| Q2 2019 | 57 |
| Q3 2019 | 57 |
| Q4 2019 | 61 |
| Q1 2020 | 66 |
| Q2 2020 | 51 |
| Q3 2020 | 45 |
| Q4 2020 | 31 |
| Q1 2021 | 58 |
| Q2 2021 | 59 |
| Q3 2021 | 62 |
| Q4 2021 | 86 |
| Q1 2022 | 80 |
| Q2 2022 | 79 |
| Q3 2022 | 82 |
| Q4 2022 | 72 |
| Q1 2023 | 34 |
Hedge funds changes in EyePoint Pharmaceuticals positions (Q2 2018 – Q1 2023)
| Q2 2018 | 32 | 0 | 1 | 0 | 1 |
|---|---|---|---|---|---|
| Q3 2018 | 10 | 6 | 9 | 10 | -1 |
| Q4 2018 | 19 | 14 | 2 | 9 | 0 |
| Q1 2019 | 18 | 18 | 13 | 6 | 1 |
| Q2 2019 | 18 | 12 | 16 | 17 | -6 |
| Q3 2019 | 9 | 22 | 11 | 8 | 7 |
| Q4 2019 | 12 | 20 | 12 | 8 | 9 |
| Q1 2020 | 12 | 26 | 17 | 6 | 5 |
| Q2 2020 | 6 | 15 | 16 | 21 | -7 |
| Q3 2020 | 4 | 7 | 15 | 10 | 9 |
| Q4 2020 | 31 | 0 | 0 | 46 | -46 |
| Q1 2021 | 33 | 15 | 4 | 6 | 0 |
| Q2 2021 | 17 | 16 | 17 | 16 | -7 |
| Q3 2021 | 10 | 20 | 19 | 7 | 6 |
| Q4 2021 | 30 | 32 | 14 | 6 | 4 |
| Q1 2022 | 9 | 30 | 24 | 15 | 2 |
| Q2 2022 | 9 | 29 | 25 | 9 | 7 |
| Q3 2022 | 11 | 25 | 24 | 8 | 14 |
| Q4 2022 | 17 | 24 | 17 | 25 | -11 |
| Q1 2023 | 5 | 9 | 10 | 9 | 1 |
Hedge funds changes in EyePoint Pharmaceuticals stock options (Q2 2018 – Q1 2023)
| Q2 2018 | 79,000 | 111,000 |
|---|---|---|
| Q3 2018 | 634,000 | 520,000 |
| Q4 2018 | 336,000 | 167,000 |
| Q1 2019 | 140,000 | 166,000 |
| Q2 2019 | 58,000 | 159,000 |
| Q3 2019 | 297,000 | 191,000 |
| Q4 2019 | 211,000 | 143,000 |
| Q1 2020 | 98,000 | 97,000 |
| Q2 2020 | 21,000 | 30,000 |
| Q3 2020 | 3,000 | 0 |
| Q4 2020 | 240,000 | 14,000 |
| Q1 2021 | 3,422,000 | 777,000 |
| Q2 2021 | 3,377,000 | 752,000 |
| Q3 2021 | 3,738,000 | 835,000 |
| Q4 2021 | 6,906,000 | 2,945,000 |
| Q1 2022 | 3,388,000 | 248,000 |
| Q2 2022 | 1,349,000 | 157,000 |
| Q3 2022 | 813,000 | 204,000 |
| Q4 2022 | 276,550 | 72,800 |
| Q1 2023 | 40,316,000 | 27,930,000 |